<?xml version='1.0' encoding='utf-8'?>
<document id="20950334"><sentence text="Nicotine and cotinine increases the brain penetration of saquinavir in rat."><entity charOffset="0-8" id="DDI-PubMed.20950334.s1.e0" text="Nicotine" /><entity charOffset="13-21" id="DDI-PubMed.20950334.s1.e1" text="cotinine" /><entity charOffset="57-67" id="DDI-PubMed.20950334.s1.e2" text="saquinavir" /><pair ddi="false" e1="DDI-PubMed.20950334.s1.e0" e2="DDI-PubMed.20950334.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20950334.s1.e0" e2="DDI-PubMed.20950334.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20950334.s1.e0" e2="DDI-PubMed.20950334.s1.e2" /><pair ddi="false" e1="DDI-PubMed.20950334.s1.e1" e2="DDI-PubMed.20950334.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20950334.s1.e1" e2="DDI-PubMed.20950334.s1.e2" /></sentence><sentence text="Endothelial tight junctions and efflux transporters of the blood-brain barrier (BBB) significantly limit brain accumulation of many drugs, including protease inhibitors such as saquinavir"><entity charOffset="177-187" id="DDI-PubMed.20950334.s2.e0" text="saquinavir" /></sentence><sentence text=" The cholinergic agonist nicotine is one of the most commonly used drugs in the world and the incidence is even higher in the human immune deficiency virus population (âˆ¼ 70%)"><entity charOffset="25-33" id="DDI-PubMed.20950334.s3.e0" text="nicotine" /></sentence><sentence text=" We examined the ability of nicotine and its primary metabolite cotinine to modify brain uptake of saquinavir in rats"><entity charOffset="28-36" id="DDI-PubMed.20950334.s4.e0" text="nicotine" /><entity charOffset="64-72" id="DDI-PubMed.20950334.s4.e1" text="cotinine" /><entity charOffset="99-109" id="DDI-PubMed.20950334.s4.e2" text="saquinavir" /><pair ddi="false" e1="DDI-PubMed.20950334.s4.e0" e2="DDI-PubMed.20950334.s4.e0" /><pair ddi="false" e1="DDI-PubMed.20950334.s4.e0" e2="DDI-PubMed.20950334.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20950334.s4.e0" e2="DDI-PubMed.20950334.s4.e2" /><pair ddi="false" e1="DDI-PubMed.20950334.s4.e1" e2="DDI-PubMed.20950334.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20950334.s4.e1" e2="DDI-PubMed.20950334.s4.e2" /></sentence><sentence text=" Both nicotine and cotinine at pharmacological concentrations matching those in smokers, increased brain saquinavir uptake by two fold"><entity charOffset="6-14" id="DDI-PubMed.20950334.s5.e0" text="nicotine" /><entity charOffset="19-27" id="DDI-PubMed.20950334.s5.e1" text="cotinine" /><entity charOffset="105-115" id="DDI-PubMed.20950334.s5.e2" text="saquinavir" /><pair ddi="false" e1="DDI-PubMed.20950334.s5.e0" e2="DDI-PubMed.20950334.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20950334.s5.e0" e2="DDI-PubMed.20950334.s5.e1" /><pair ddi="false" e1="DDI-PubMed.20950334.s5.e0" e2="DDI-PubMed.20950334.s5.e2" /><pair ddi="false" e1="DDI-PubMed.20950334.s5.e1" e2="DDI-PubMed.20950334.s5.e1" /><pair ddi="false" e1="DDI-PubMed.20950334.s5.e1" e2="DDI-PubMed.20950334.s5.e2" /></sentence><sentence text=" Co-perfusion with nicotinic receptor antagonists and passive permeability markers showed that the effect was not caused by receptor activation or BBB permeability disruption" /><sentence text=" Transport inhibition studies demonstrated that brain saquinavir uptake is limited by multiple efflux transporters, P-glycoprotein (P-gp), breast cancer resistance protein and multidrug resistance-associated protein"><entity charOffset="54-64" id="DDI-PubMed.20950334.s7.e0" text="saquinavir" /></sentence><sentence text=" In situ perfusion and in vitro experiments using a classical P-gp substrate rhodamine 123 linked the effect of nicotine to inhibition of BBB P-gp transport"><entity charOffset="112-120" id="DDI-PubMed.20950334.s8.e0" text="nicotine" /></sentence><sentence text=" The effect was confirmed in vivo in chronic 14 day nicotine administration animals"><entity charOffset="52-60" id="DDI-PubMed.20950334.s9.e0" text="nicotine" /></sentence><sentence text=" These data suggest nicotine increases antiretroviral drug exposure to brain and may represent a significant in vivo drug-drug interaction at the BBB"><entity charOffset="20-28" id="DDI-PubMed.20950334.s10.e0" text="nicotine" /></sentence><sentence text=" Although this may slightly benefit CNS antiretroviral efficacy, it may also expose the brain to potential serious neurotoxicity" /><sentence text="" /></document>